An innovative platform allowing patients to consent to data reuse, reducing clinical trial recruitment timeline by 50% and saving customers up to £150M

An%20创新%20平台%20允许%20患者%20to%20同意%20to%20数据%20重用、%20减少%20临床%20试验%20招募%20时间线%20by%2050%%20和%20节省%20客户%20up%20to%20£1.5亿

• 批准号: 10073046
• 金额: $ 50.92万
• 依托单位: GENEHUB LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10073046
• 关键词: innovative; platform; allowing; patients; consent

GENEHUB LTD (GeneHub) is a UK-based Pharmatech SME with a core project team of Edward Straiton (CPO/project lead), Nicolo Maioli (technical lead), Paavan Buddhdev (UX/UI lead) and Craig Coulton (CEO/commercial lead). GeneHub is solving a significant unmet need with its innovative data-sharing platform that brings Pharma/Biotech analysis to where patient data resides, maintaining patient privacy and data security and accelerating patient benefits. Using OMIX, patients consent to reuse their genomic+clinical data across clinical trials, negating secondary data use restrictions that currently result in wasted patient data. Reducing the time required to screen and recruit patients to clinical trials and prevent data wastage will accelerate clinical trials, address the UK's decline in clinical trials started (recently falling from 4th to 10th globally) and save patient lives. This direct-to-patient platform will be the first built explicitly for clinical trials using genomic+clinical data and will focus on informed consent and data reuse using privacy-preserving technologies.

GENEHUB LTD（GeneHub）是一家总部位于英国的制药技术中小企业，其核心项目团队包括Edward Straiton（CPO/项目负责人）、Nicolo Maioli（技术负责人）、Paavan Kidney dev（UX/UI负责人）和克雷格库尔顿（CEO/商业负责人）。GeneHub正在通过其创新的数据共享平台解决一个重大的未满足的需求，该平台将制药/生物技术分析带到患者数据所在的位置，维护患者隐私和数据安全，并加速患者利益。使用OMIX，患者同意在临床试验中重复使用他们的基因组+临床数据，否定了目前导致患者数据浪费的二级数据使用限制。减少筛选和招募患者参加临床试验所需的时间，并防止数据浪费，将加速临床试验，解决英国临床试验开始数量下降的问题（最近从全球第4位下降到第10位），并挽救患者生命。这个直接面向患者的平台将是第一个明确为使用基因组+临床数据的临床试验而构建的平台，并将专注于使用隐私保护技术的知情同意和数据重用。